TY - JOUR
T1 - Gaucher disease
T2 - When molecular testing and clinical presentation disagree -the novel c.1226A>G(p.N370S) - RecNcil allele
AU - Balwani, Manisha
AU - Grace, Marie E.
AU - Desnick, Robert J.
N1 - Funding Information:
receives research and training grants from, the Genzyme Corporation, and has founder shares in Amicus Therapeutics, Inc. Mount Sinai school of Medicine, the Department of Genetics and Genomic Sciences and some faculty members in the department (including the Chair and Dean for Genetics and Genomics, Dr. Robert Desnick) receive financial benefit from the Genzyme Corporation for the sale of Fabrazyme®, an enzyme replacement drug developed by them for the treatment of Fabry disease. MB is a member of the ICGG North American advisory board and has received an honorarium from Genzyme. Other authors declare no competing interests.
PY - 2011/6
Y1 - 2011/6
N2 - We report a 31 year old woman who had prenatal carrier screening for Ashkenazi Jewish (AJ) genetic diseases and was found to have two acid ß-glucosidase (GBA) mutations, c.1226A>G(p.N370S) and c.1448T>C(p.L444P), consistent with the diagnosis of Type 1 Gaucher disease (GD1). This genotype typically manifests in late-adolescence with hepatosplenomegaly and early-onset bone involvement. The Proband had a normal physical examination, no organomegaly, and normal blood counts, skeletal survey, and bone density. Leukocyte acid ß-glucosidase and plasma chitotriosidase activities were normal. To investigate these unexpected results, her GBA alleles were RT-PCR amplified and sequenced. Five RT-PCR clones were negative for both mutations, while five clones had the c.1226A>G(p.N370S) and c.1448T>C(p.L444P) mutations, along with c.1483G>C(p.A456P), and c.1497G>C(p.V460V) mutations, the latter three lesions composing the rare GBA pseudogene-derived RecNcil allele. Genetic testing misdiagnosed the asymptomatic Proband as affected with Type 1 Gaucher disease; however, molecular studies revealed a novel allele with the two common GBA mutations on the RecNcil background. This allele presumably arose by crossing-over between a c.1226A>G allele and the pseudogene, gene conversion, or a new c.1226A>G mutation on the RecNcil background. This novel complex allele highlights a limitation of carrier screening for GD.
AB - We report a 31 year old woman who had prenatal carrier screening for Ashkenazi Jewish (AJ) genetic diseases and was found to have two acid ß-glucosidase (GBA) mutations, c.1226A>G(p.N370S) and c.1448T>C(p.L444P), consistent with the diagnosis of Type 1 Gaucher disease (GD1). This genotype typically manifests in late-adolescence with hepatosplenomegaly and early-onset bone involvement. The Proband had a normal physical examination, no organomegaly, and normal blood counts, skeletal survey, and bone density. Leukocyte acid ß-glucosidase and plasma chitotriosidase activities were normal. To investigate these unexpected results, her GBA alleles were RT-PCR amplified and sequenced. Five RT-PCR clones were negative for both mutations, while five clones had the c.1226A>G(p.N370S) and c.1448T>C(p.L444P) mutations, along with c.1483G>C(p.A456P), and c.1497G>C(p.V460V) mutations, the latter three lesions composing the rare GBA pseudogene-derived RecNcil allele. Genetic testing misdiagnosed the asymptomatic Proband as affected with Type 1 Gaucher disease; however, molecular studies revealed a novel allele with the two common GBA mutations on the RecNcil background. This allele presumably arose by crossing-over between a c.1226A>G allele and the pseudogene, gene conversion, or a new c.1226A>G mutation on the RecNcil background. This novel complex allele highlights a limitation of carrier screening for GD.
UR - http://www.scopus.com/inward/record.url?scp=79959799166&partnerID=8YFLogxK
U2 - 10.1007/s10545-011-9307-7
DO - 10.1007/s10545-011-9307-7
M3 - Article
C2 - 21431620
AN - SCOPUS:79959799166
SN - 0141-8955
VL - 34
SP - 789
EP - 793
JO - Journal of Inherited Metabolic Disease
JF - Journal of Inherited Metabolic Disease
IS - 3
ER -